var data={"title":"Levetiracetam: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levetiracetam: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6447?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">see &quot;Levetiracetam: Drug information&quot;</a> and <a href=\"topic.htm?path=levetiracetam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levetiracetam: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187641\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Keppra;</li>\n      <li>Keppra XR;</li>\n      <li>Roweepra;</li>\n      <li>Roweepra XR;</li>\n      <li>Spritam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187642\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abbott-Levetiracetam;</li>\n      <li>ACT Levetiracetam;</li>\n      <li>Apo-Levetiracetam;</li>\n      <li>Auro-Levetiracetam;</li>\n      <li>Dom-Levetiracetam;</li>\n      <li>JAMP-Levetiracetam;</li>\n      <li>Keppra;</li>\n      <li>PHL-Levetiracetam;</li>\n      <li>PMS-Levetiracetam;</li>\n      <li>PRO-Levetiracetam;</li>\n      <li>RAN-Levetiracetam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2875435\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443805\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neonatal Seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Limited data available: 10 mg/kg/day divided twice daily; increase dosage by 10 mg/kg over 3 days to 30 mg/kg/day; additional increases up to 45 to 60 mg/kg/day have been used with persistent seizure activity or clinical EEG findings. Dosing based on an open-label study of 38 patients (n=19 premature neonates GA &lt;28 weeks [birth weight: 0.41 to 1.33 kg]; n=6 premature neonates GA: 28 to 36 weeks [birth weight: 1.25 to 1.89 kg]; n=13 term neonates) which reported a decrease in seizure frequency (ie, after 1 week of therapy, 30/38 patients were seizure-free). The investigators noted that patients with extensive intracerebral hemorrhage tended to be less responsive to therapy (Ramantani 2011). A case series of eight neonates (GA range: 22 weeks to term) with refractory neonatal seizures reported a dose range of 10 to 35 mg/kg/day (Rakshasbhuvankar 2013). For treatment of status epilepticus, loading doses of 20 to 30 mg/kg/dose have been used by some centers (Abend 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Limited data available: Initial: 10 mg/kg/day in 1 to 2 divided doses; increase daily by 10 to 30 mg/kg/day (maximum reported dose: 60 mg/kg/day). Dosing based on two prospective, open-label studies (n=38 [n=19, GA: &lt;28 weeks; n=6, GA: 28 to 36 weeks, n=13 term]; n=6, GA: &gt;30 weeks), a case series (n=3, 2 days to 3 months) which showed levetiracetam was effective at increasing seizure-free interval, and a report of pediatric neurologists' NICU experience (F&uuml;rwentsches 2010; Ramantani 2011; Shoemaker 2007; Silverstein 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2875546\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">see &quot;Levetiracetam: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Use oral solution in infants and children &le;20 kg. Parenteral IV therapy should be temporary and transitioned to oral when able; when switching from oral to IV formulation, the total daily dose should be the same.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myoclonic seizures with juvenile myoclonic epilepsy:</b> Children &ge;12 years and Adolescents: IV, Oral <i>(immediate release: Tablets, oral solution [eg, Keppra], or tablets for oral suspension [Spritam])</i>: Initial 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily, to the recommended dose of 1,500 mg twice daily. Efficacy of doses &lt;3,000 mg/day has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial onset seizures: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 to &lt;6 months: IV, Oral <i>(immediate release: Solution)</i>: Initial: 7 mg/kg/dose twice daily; increase dosage every 2 weeks by 7 mg/kg/dose twice daily as tolerated, to the recommended dose of 21 mg/kg/dose twice daily; effectiveness of lower doses has not been established; during clinical trials, the mean daily dose was 35 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months and Children &lt;4 years: IV, Oral <i>(immediate release: Solution or tablets)</i>: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily, as tolerated, to the recommended dose of 25 mg/kg/dose twice daily; may reduce daily dose if not tolerated; during clinical trials, the mean daily dose was 47 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;4 years and Adolescents &lt;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily, as tolerated, to a maximum of 30 mg/kg/dose twice daily; maximum daily dose: 3,000 mg/<b>day</b>; may reduce daily dose if not tolerated; during clinical trials, the mean daily dose was 44 mg/kg/<b>day</b>; in older pediatric patients and adults (eg, weight &gt;50 kg), an initial fixed dose of 500 mg twice daily is suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: <i>Oral solution</i>: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily, as tolerated, to a maximum of 30 mg/kg/dose twice daily; maximum daily dose: 3,000 mg/<b>day</b>; may reduce daily dose if not tolerated; during clinical trials, the mean daily dose was 44 mg/kg/<b>day</b>; in older pediatric patients and adults (eg, weight &gt;50 kg), an initial fixed dose of 500 mg twice daily is suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fixed dosing: <i>Tablet (immediate release [eg, Keppra] or for oral suspension [Spritam])</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">20 to 40 kg: Initial: 250 mg twice daily; increase every 2 weeks by 250 mg twice daily to the maximum recommended dose of 750 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;40 kg: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg twice daily to the maximum recommended dose of 1,500 mg twice daily. Additional benefit with doses &gt;3,000 mg/<b>day</b> has not been shown.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release<i> (eg, Elepsia XR; Keppra XR)</i>: Children &ge;12 years and Adolescents: Initial: 1,000 mg once daily; may increase every 2 weeks by 1,000 mg/day to a maximum of 3,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose twice daily, if tolerated, to a maximum dose of 1,500 mg twice daily. Efficacy of doses &gt;3,000 mg/<b>day</b> has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release <i>(tablets, oral solution [eg, Keppra], tablets for oral suspension [Spritam])</i>: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg twice daily to the maximum recommended dose of 1,500 mg twice daily. Efficacy of doses &gt;3,000 mg/<b>day</b> has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release <i>(eg, Elepsia XR, Keppra XR)</i>: Initial: 1,000 mg once daily; increase every 2 weeks by 1,000 mg/day to a maximum of 3,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tonic-clonic seizures; primary generalized:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and Adolescents &lt;16 years</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily to the recommended dose of 30 mg/kg/dose twice daily. Efficacy of doses &lt;60 mg/kg/day has not been established. In older pediatric patients and adults (eg, weight &gt;50 kg), an initial fixed dose of 500 mg twice daily is suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed: <i>Oral solution or tablets:</i> Initial: 10 mg/kg/dose twice daily; increase dosage every 2 weeks by 10 mg/kg/dose twice daily to the recommended dose of 30 mg/kg/dose twice daily. Efficacy of doses &lt;60 mg/kg/day has not been established. In pediatric patients and adults (eg, weight &gt;50 kg), an initial fixed dose of 500 mg twice daily is suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed-dosing: <i>Orally disintegrating tablets [Spritam]:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to 40 kg: Initial: 250 mg twice daily; increase every 2 weeks by 250 mg twice daily to the maximum recommended dose of 750 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;40 kg: Initial: 500 mg twice daily; increase every 2 weeks by 500 mg twice daily to the maximum recommended dose of 1,500 mg twice daily. Efficacy of doses &lt;3,000 mg/<b>day</b> has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;16 years: IV, Oral <i>(immediate release: Solution or tablets [eg, Keppra], tablets for oral suspension [Spritam]):</i> Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily to the recommended dose of 1,500 mg twice daily. Efficacy of doses &lt;3,000 mg/<b>day</b> has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus or acute repetitive seizure activity:</b> Limited data available: Infants, Children, and Adolescents: IV: Usual initial range: 20 to 60 mg/kg; dose should not exceed adult initial range: 1,000 to 3,000 mg (NCS [Brophy 2012]); based on reported experience, the following has been used: Loading dose: 50 mg/kg/dose (maximum dose: 2,500 mg/dose), followed by IV or oral maintenance dosing determined by clinical response; reported IV maintenance dose: 30 to 55 mg/kg/day divided twice daily (Kirmani 2009; Ng 2010). Dosing based on a prospective study (n=30, 6 months to &lt;15 years), several retrospective observations, and case reports (n &gt;100; youngest patient: 1 day old; reported loading dose range: 6.5 to 89 mg/kg) (Abend 2009; Gallentine 2009; Goraya 2008; Kirmani 2009; Ng 2010; Reiter 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myoclonic seizures:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose twice daily to the recommended dose of 1,500 mg twice daily. Efficacy of doses other than 3,000 mg/<b>day</b> has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily to the recommended dose of 1,500 mg twice daily. Efficacy of doses other than 3,000 mg/day has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Partial onset seizures: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose twice daily to the maximum recommended dose of 1,500 mg twice daily. Efficacy of doses &gt;3,000 mg/<b>day</b> has not established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 1,000 mg once daily; increase every 2 weeks by 1,000 mg/day to a maximum of 3,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 500 mg twice daily; may increase every 2 weeks by 500 mg/dose twice daily to a maximum of 1,500 mg twice daily. Doses &gt;3,000 mg/day have been used in trials; however, there is no evidence of increased benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tonic-clonic seizures: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release (tablets, oral solution, tablets for oral suspension): Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily to the recommended dose of 1,500 mg twice daily. Efficacy of doses &lt;3,000 mg/<b>day</b> has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 500 mg twice daily; increase dosage every 2 weeks by 500 mg/dose twice daily to the recommended dose of 1,500 mg twice daily. Efficacy of doses other than 3,000 mg/<b>day </b>has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &lt;16 years: There are no dosage adjustments provided in the manufacturer's labeling; clearance is decreased and correlates with creatinine clearance. Some have recommended the following for immediate release tablets, oral solution, and IV (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of the dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Dialyzable (50%). Administer 50% of normal dose every 24 hours; a supplemental dose after hemodialysis is recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CAPD: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CRRT: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;16 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, Oral <i>(Immediate release [tablets, solution] and tablets for oral suspension [Spritam])</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;80 mL/minute/1.73 m<sup>2</sup>: 500 to 1,500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 50 to 80 mL/minute/1.73 m<sup>2</sup>: 500 to 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 250 to 750 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 250 to 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End-stage renal disease patients using dialysis: Dialyzable (50%); 500 to 1,000 mg every 24 hours; a supplemental dose of 250 to 500 mg following dialysis is recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 500 to 1,000 mg every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 250 to 750 mg every 12 hours (Arnoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release tablets: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Elepsia XR:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;80 mL/minute/1.73 m<sup>2</sup>: 1,000 to 3,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 50 to 80 mL/minute/1.73 m<sup>2</sup>: 1,000 to 2,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;50 mL/minute/1.73 m<sup>2</sup>: Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Keppra XR and similar generics: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;80 mL/minute/1.73 m<sup>2</sup>: 1,000 to 3,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 50 to 80 mL/minute/1.73 m<sup>2</sup>: 1,000 to 2,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 500 to 1,500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 500 to 1,000 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">End-stage renal disease patients using dialysis: Dialyzable (50%). Use immediate release product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187617\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 500 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/100 mL (100 mL); 1000 mg/100 mL (100 mL); 1500 mg/100 mL (100 mL); 500 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 100 mg/mL (473 mL) [gluten free, lactose free; contains acesulfame potassium, methylparaben, propylparaben; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (5 mL, 473 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 250 mg [scored; contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 750 mg [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra: 1000 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra: 750 mg [contains corn starch, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra: 1000 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 750 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating Soluble, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spritam: 250 mg, 500 mg, 750 mg, 1000 mg [spearmint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra XR: 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Roweepra XR: 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 750 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187603\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46216158\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">see &quot;Levetiracetam: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b>  Tablets for oral suspension and soluble disintegrating tablet both refer to Spritam.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874650\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Keppra: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s099,021505s038lbl.pdf#page=28&amp;token=h/GoBDroawDA3c9N+L0xZ4M333INnOBqQPFPvpWT92YUXr9byQQKQ2wxdtVEzuqskdPFEOqioXWzjrxMLSchK8uQGr9VuUHPDGX2ah36J18t7GQ0nJyqx/pYnuYtStQV&amp;TOPIC_ID=12910\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s099,021505s038lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Keppra XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022285s025lbl.pdf#page=21&amp;token=Vuxfsa80ZLCc35D6scNhif81X0+hPqgX4vdz4APcUBBpSqsTXcnaFhi76K0quh0T1nDpA0HFxeoN3n5lXETRhvKQTnI5/m+6P6WzKyndX66sEFEEO15SsecVwVsfUoSh&amp;TOPIC_ID=12910\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022285s025lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Spritam: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM487803.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giXO38s8SakPIVPdnI0lcPgw==&amp;TOPIC_ID=12910\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM487803.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2875547\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to meals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release and extended release tablets: Swallow tablets whole; do not break, crush, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Administer with calibrated measuring device (not household teaspoon or tablespoon). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets for oral suspension (Spritam): Remove from blister by peeling back the foil (do not push tablet through the foil). Place whole tablet on the tongue with dry hand; follow with a sip of liquid and swallow only after tablet disintegrates; do not swallow intact tablet. Partial/split tablets should not be administered. Tablet disintegrates in a mean time of 11 seconds (ranging from 2 to 27 seconds) in the mouth when taken with a sip of liquid.  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternatively, allow whole tablet to disperse in a small volume of liquid (eg, 15 mL or enough to cover the tablet[s]) in a cup; consume entire contents immediately; resuspend any residue in cup by adding an additional small volume of liquid and swallow the full amount</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: Vials must be diluted prior to use. Do not use if solution contains particulate matter or is discolored. Discard unused portions; does not contain preservative. Infuse over 15 minutes (Ng 2010); in status epilepticus a rate of 2 to 5 mg/kg/minute has been recommended (NCS [Brophy 2012]). Others have safely used a 1:1 dilution infused over 5 to 6 minutes (with doses up to 60 mg/kg) through a peripheral site in patients 4 to 32 years of age (Wheless 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187636\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution, tablets, tablets for oral suspension: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Premixed solution for infusion: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Vials for injection: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Admixed solution in NS, LR, or D5W is stable for 4 hours in PVC bags kept at room temperature (<b>Note:</b> The manufacturer's labeling for Keppra injection previously stated the admixed solution is stable for 24 hours in PVC bags at room temperature; this was changed to 4 hours as of April 2016 although there was no change in the formulation (Personal Communication, UCB, Inc. 2016). The manufacturer&rsquo;s labeling for generic levetiracetam injectable products may have differing recommendations; refer to individual manufacturer&rsquo;s labeling for details. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2875436\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution and immediate release tablets: Adjunctive therapy in the treatment of partial onset seizures (FDA approved in ages &ge;1 month and adults); adjunctive therapy in the treatment of myoclonic seizures (including juvenile myoclonic epilepsy) (FDA approved in ages &ge;12 years and adults); adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (FDA approved in ages &ge;6 years and adults); has also been used for treatment of neonatal seizures</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets for oral suspension: Spritam: Adjunctive therapy in the treatment of partial onset seizures (FDA approved in ages &ge;4 years weighing &gt;20 kg and adults); adjunctive therapy in the treatment of juvenile myoclonic epilepsy (FDA approved in ages &ge;12 years); and adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (FDA approved in ages &ge;6 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablets (eg, Elepsia XR, Keppra XR): Adjunctive therapy in the treatment of partial onset seizures (FDA approved in ages &ge;12 years and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Adjunctive therapy when oral administration is temporarily not feasible in the treatment of partial onset seizures (FDA approved in ages &ge;1 month and adults), myoclonic seizures (including juvenile myoclonic epilepsy) (FDA approved in ages &ge;12 years and adults), primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy (FDA approved in ages &ge;6 years and adults); has also been used for treatment of refractory status epilepticus or acute repetitive seizure activity </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187675\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keppra may be confused with Keflex, Keppra XR</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LevETIRAcetam may be confused with lamoTRIgine, levOCARNitine, levoFLOXacin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Potential for dispensing errors between Keppra and Kaletra (lopinavir/ritonavir)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187673\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Information given for all indications and populations (adults and children) unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Increased blood pressure (diastolic; infants and children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aggressive behavior (children and adolescents), agitation (children and adolescents), amnesia, anxiety, ataxia (partial-onset seizures; includes abnormal gait, incoordination), behavioral problems (includes aggression, agitation, anger, anxiety, apathy, depersonalization, emotional lability, irritability, neurosis), confusion, depression, dizziness, drowsiness, emotional lability, falling (children and adolescents), fatigue, headache, hostility, insomnia (children and adolescents), irritability (infants, children, and adolescents), lethargy (children and adolescents), mood changes (children and adolescents), nervousness, pain, paranoia (children and adolescents), paresthesia, psychotic symptoms, sedation (children and adolescents), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation (children and adolescents), decreased appetite (children and adolescents), diarrhea, gastroenteritis (children and adolescents), nausea, upper abdominal pain (children and adolescents), vomiting (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise (children and adolescents), decreased neutrophils, decreased white blood cell count, eosinophilia (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (children and adolescents), joint sprain (children and adolescents), neck pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis (children and adolescents), diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, nasal congestion (children and adolescents), nasopharyngitis, pharyngolaryngeal pain (children and adolescents), pharyngitis, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Head trauma (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, acute renal failure, agranulocytosis, alopecia, anaphylaxis, angioedema, blurred vision, choreoathetosis, decreased hematocrit, decreased hemoglobin, decreased red blood cells, disturbance in attention, DRESS syndrome, dyskinesia, eczema, equilibrium disturbance, erythema multiforme, granulomatous interstitial nephritis (Chau 2012), hepatic failure, hepatitis, hyperkinesia, hyponatremia, leukopenia, memory impairment, myalgia, myasthenia, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression in some cases), panic attack, personality disorder, pruritus, psychosis, skin rash, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, thrombocytopenia, toxic epidermal necrolysis, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187623\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis, angioedema) to levetiracetam or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187607\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression (impaired coordination, ataxia, abnormal gait, weakness, fatigue, dizziness, and somnolence), which may impair physical or mental abilities. Symptoms occur most commonly during the first month of therapy. Patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported in adults and children. Onset is usually within ~2 weeks of treatment initiation, but may be delayed (&gt;4 months); recurrence following rechallenge has been reported. Levetiracetam should be discontinued if there are any signs of a hypersensitivity reaction or unspecified rash; if signs or symptoms suggest SJS or TEN, do not resume therapy and consider alternative treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Decreases in red blood cell counts, hemoglobin, hematocrit, white blood cell counts, and neutrophils and increases in eosinophils have been observed. Cases of, agranulocytosis, pancytopenia, and thrombocytopenia have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Potentially life-threatening hypersensitivity reactions, including anaphylaxis, angioedema, hypotension, hives, rash and respiratory distress may occur after the first dose or at any time during treatment. If signs or symptoms of anaphylaxis or angioedema occur, discontinue levetiracetam immediately. If a clear alternative etiology for the symptoms cannot be determined, discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Isolated elevations in diastolic blood pressure measurements have been reported in children &lt;4 years; however, no observable differences were noted in mean diastolic measurements of children receiving levetiracetam vs placebo. Similar effects have not been observed in older children and adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric symptoms: Psychosis, paranoia, hallucinations and behavioral symptoms (including aggression, agitation, anger, anxiety, apathy, confusion, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, and personality disorder) may occur; dose reduction or discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution with renal impairment; dosage adjustment may be necessary. In patients with ESRD requiring hemodialysis, it is recommended that immediate-release formulations be used instead of ER formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may have increased incidence of psychiatric symptoms; dose reduction or discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022046\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence of behavioral abnormalities is higher in children (37.6%) than adults (13.3%); dosage reductions may be required. In clinical trials, pediatric patients 4 to &lt;16 years, when compared with placebo, had statistically significant decreases in WBC and neutrophil counts; in one clinical trial, possible clinically significant decreases in WBCs were observed, but no difference in neutrophil counts was observed. Isolated elevations in diastolic blood pressure (DBP) measurements have been reported in infants and children 1 month to &lt;4 years of age receiving levetiracetam; however, no difference was noted in mean diastolic measurements of these patients vs placebo group; monitor blood pressure in infants and children &lt;4 years. Similar effects have not been observed in older children and adults. In pediatric clinical trials, the most frequently reported adverse reactions in pediatric patients 4 to &lt;16 years of age were fatigue, aggression, nasal congestion, decreased appetite, and irritability and in younger pediatric patients (1 month to &lt;4 years of age) were somnolence and irritability; additionally, children may experience a higher frequency of certain adverse effects than adults, including the following: Behavioral abnormalities (37.6% vs 13.3%), aggression/hostility (10% vs 2%), vomiting (reported in children only, 15%), and cough (9% vs 2%).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A retrospective chart review of 280 neonates who had received either phenobarbital, levetiracetam, or both for treatment of neonatal seizures evaluated neurodevelopment. A subset of the study group (n=67) had a Bayley Scales of Infant Development (BSID) completed at 24 months corrected age. Based on the analysis of cumulative exposures, the investigators observed that increased levetiracetam exposure was associated with a significant decrease in BSID cognitive (2.2 points) and motor (2.6 points) scores for every 300 mg/kg of levetiracetam exposure and no increased incidence of cerebral palsy was observed; however, increased neonatal exposure to phenobarbital was associated with larger significant reductions in BSID cognitive and motor scores (8 to 9 points) and an increased probability for the development of cerebral palsy. Since most patients received both drugs and thus were included in both evaluation groups and due to the retrospective design, a direct causality between levetiracetam exposure and negative cognitive and motor outcomes could not be confirmed (Maitre 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299586\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187612\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12910&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brivaracetam: LevETIRAcetam may diminish the therapeutic effect of Brivaracetam. Specifically, the therapeutic effect of brivaracetam may be diminished and/or negligible when given to patients already receiving levetiracetam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: LevETIRAcetam may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: LevETIRAcetam may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of LevETIRAcetam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187637\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may delay, but does not affect the extent of absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187614\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187626\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. Levetiracetam crosses the placenta and can be detected in the newborn following delivery (Johannessen 2005; Lopez-Fraile 2009; Tomson 2007). An increase in the overall rate of major congenital malformations has not been observed following maternal use of levetiracetam. Available studies have not been large enough to determine if there is an increased risk of specific birth defects (Hernandez-Diaz 2012; Mawhinney 2013; M&oslash;lgaard-Nielsen 2011; Vajda 2012). In general, maternal polytherapy with antiepileptic drugs may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended. Newborns of women taking antiepileptic medications may be at an increased risk of SGA and a 1 minute APGAR score &lt;7 (Harden and Meader 2009). Plasma concentrations of levetiracetam gradually decrease during pregnancy, especially during the third trimester, due to physiologic changes which occur; patients should be monitored during pregnancy and postpartum. </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">A registry is available for women exposed to levetiracetam during pregnancy: Pregnant women may enroll themselves into the North American Antiepileptic Drug (AED) Pregnancy Registry (888-233-2334 or http://www.aedpregnancyregistry.org/). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2875551\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Seizure frequency, duration, and severity; CNS depression; psychiatric and behavioral symptoms; diastolic blood pressure in pediatric patients &lt;4 years of age; renal function; CBC; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187606\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown. However, several studies have suggested the mechanism may involve one or more of the following central pharmacologic effects: inhibition of voltage-dependent N-type calcium channels; facilitation of GABA-ergic inhibitory transmission through displacement of negative modulators; reduction of delayed rectifier potassium current; and/or binding to synaptic proteins which modulate neurotransmitter release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187622\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid and almost complete</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Food decreases C<sub>max</sub> by 20% and delays time to C<sub>max</sub> (T<sub>max</sub>) by 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Intake of a high-fat, high-calorie breakfast before the administration results in a higher C<sub>max</sub> and longer median T<sub>max</sub>; the median T<sub>max</sub> is 2 hours longer in the fed state</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Similar to total body water</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;4 years: 0.63 &plusmn; 0.08 L/kg (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 6 to 12 years: 0.72 &plusmn; 0.12 L/kg (Pellock 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.5 to 0.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not extensive; 24% of dose is metabolized by enzymatic hydrolysis of acetamide group (major metabolic pathway; hydrolysis occurs primarily in the blood; not cytochrome P450 dependent); two minor metabolites (one via hydroxylation of 2-oxo-pyrrolidine ring and one via opening of the 2-oxo-pyrrolidine ring in position 5) are also formed; metabolites are inactive and renally excreted</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 100%; bioavailability of extended release tablets is similar to immediate release tablets; tablets, oral solution, and injection are bioequivalent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Increased in patients with renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;4 years: 5.3 &plusmn; 1.3 hours (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 4 to 12 years: 6 &plusmn; 1.1 hours (Pellock 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~6 to 8 hours; extended release tablet: ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Fasting infants and children &lt;4 years: 1.4 &plusmn; 0.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: Fasting adults and children: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Extended release: ~4 hours; median time to peak is 2 hours longer in the fed state</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (66% as unchanged drug and 27% as inactive metabolites); undergoes glomerular filtration and subsequent partial tubular reabsorption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Correlated with creatinine clearance; clearance is decreased in patients with renal dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 months: 1.23 mL/minute/kg (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 6 months to 4 years: 1.57 mL/minute/kg (Glauser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: 1.43 mL/minute/kg; 30% to 40% higher than adults on a per kg basis (Pellock 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187625\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Keppra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (5 mL): $63.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Keppra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (473 mL): $861.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevETIRAcetam in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL (100 mL): $33.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/100 mL (100 mL): $54.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 mg/100 mL (100 mL): $72.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevETIRAcetam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (5 mL): $4.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevETIRAcetam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (473 mL): $307.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Disintegrating Soluble</b> (Spritam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $575.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Keppra XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $513.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $770.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (LevETIRAcetam ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $266.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $400.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Roweepra XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $266.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (60): $400.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Keppra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (120): $926.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $1,132.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (120): $1,534.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $1,132.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevETIRAcetam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (120): $345.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $421.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (120): $571.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $422.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Roweepra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (120): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $120.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187628\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Callexe (AR);</li>\n      <li>Callexe XR (AR);</li>\n      <li>Ceumid (CR, DO, EC, GT, HN, NI, PA, SV, UY);</li>\n      <li>Citazar (BD);</li>\n      <li>Desitrend (GB);</li>\n      <li>Dretacen (NL);</li>\n      <li>E Keppra (JP);</li>\n      <li>Eletam (BD);</li>\n      <li>Epictal (IN);</li>\n      <li>Epilen (TW);</li>\n      <li>Epiletam (RO);</li>\n      <li>Epilev (HR);</li>\n      <li>Epsytam (PH);</li>\n      <li>Erata (BD);</li>\n      <li>Iracet (BD, LK);</li>\n      <li>Ivetra (PH);</li>\n      <li>Julitam (PH);</li>\n      <li>Kepcet (AU, DE);</li>\n      <li>Kepdin (PH);</li>\n      <li>Keppra (AE, AR, AT, AU, BB, BE, BG, BH, BM, BS, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TT, TW, UA, VN);</li>\n      <li>Keppra I.V. (AU);</li>\n      <li>Keppra XR (BB);</li>\n      <li>Kerron (AU);</li>\n      <li>Kevesy (NL);</li>\n      <li>Kevtam (AU);</li>\n      <li>Kopodex (CL, CO, EC, PE, PY);</li>\n      <li>Laurak (ES);</li>\n      <li>Lecetam (TH);</li>\n      <li>Lethira (ID);</li>\n      <li>Letram (PH);</li>\n      <li>Lev Desitin (CH);</li>\n      <li>Levetam (UY);</li>\n      <li>Levetrim (IL);</li>\n      <li>Levetstad (VN);</li>\n      <li>Levim (TW);</li>\n      <li>Levipil (LK);</li>\n      <li>Levit (PH);</li>\n      <li>Levitam (ID);</li>\n      <li>Levron (AR);</li>\n      <li>Malomibe (VN);</li>\n      <li>Matever (EE, IE, MT, SE);</li>\n      <li>Nobelin (TW);</li>\n      <li>Normeg (EE);</li>\n      <li>Prepalepan (AT);</li>\n      <li>Repitend (EE);</li>\n      <li>Rivolev (UA);</li>\n      <li>Rivoleve (CH);</li>\n      <li>Tietari (SG);</li>\n      <li>Tiramaks (UA);</li>\n      <li>Torleva (IN, LK, VN);</li>\n      <li>Trund (NL);</li>\n      <li>Vexlev (PH);</li>\n      <li>Vitera (RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abend NS, Monk HM, Licht DJ, et al, &quot;Intravenous Levetiracetam in Critically Ill Children With Status Epilepticus or Acute Repetitive Seizures,&quot; <i>Pediatr Crit Care Med</i>, 2009, 10(4):505-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19325512/pubmed\" target=\"_blank\" id=\"19325512\">19325512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007, 89, 165.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22528274 /pubmed\" target=\"_blank\" id=\"22528274 \">22528274 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elepsia XR (levetiracetam) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    F&uuml;rwentsches A, Bussmann C, Ramantani G, et al, &quot;Levetiracetam in the Treatment of Neonatal Seizures: A Pilot Study,&quot; <i>Seizure</i>, 2010, 19(3):185-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/20133173/pubmed\" target=\"_blank\" id=\"20133173\">20133173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallentine WB, Hunnicutt AS, and Husain AM, &quot;Levetiracetam in Children With Refractory Status Epilepticus,&quot; <i>Epilepsy Behav</i>, 2009, 14(1):215-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18926926/pubmed\" target=\"_blank\" id=\"18926926\">18926926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser TA, Mitchell WG, Weinstock A, et al, &quot;Pharmacokinetics of Levetiracetam in Infants and Young Children With Epilepsy,&quot; <i>Epilepsia</i>, 2007, 48(6):1117-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17442002/pubmed\" target=\"_blank\" id=\"17442002\">17442002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goraya JS, Khurana DS, Valencia I, et al, &quot;Intravenous Levetiracetam in Children With Epilepsy,&quot; <i>Pediatr Neurol</i>, 2008, 38(3):177-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18279751/pubmed\" target=\"_blank\" id=\"18279751\">18279751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grosso S, Cordelli DM, Franzoni E, et al, &quot;Efficacy and Safety of Levetiracetam in Infants and Young Children With Refractory Epilepsy,&quot; <i>Seizure</i>, 2007, 16(4):345-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17368928/pubmed\" target=\"_blank\" id=\"17368928\">17368928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-D&iacute;az S, Smith CR, Shen A, et al, &quot;Comparative Safety of Antiepileptic Drugs During Pregnancy,&quot; <i>Neurology</i>, 2012, 8(21):1692-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22551726/pubmed\" target=\"_blank\" id=\"22551726\">22551726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. <i>Epilepsia</i>. 2005;46(5):775-777.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/15857447 /pubmed\" target=\"_blank\" id=\"15857447 \">15857447 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra injection (levetiracetam) [prescribing information]. Smyrna, GA: UCB, Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra tablets (levetiracetam) [prescribing information]. Smyrna, GA: UCB, Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keppra tablets, oral solution (levetiracetam) [prescribing information]. Smyrna, GA: UCB, Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirmani BF, Crisp ED, Kayani S, et al, &quot;Role of Intravenous Levetiracetam in Acute Seizure Management of Children,&quot; <i>Pediatr Neurol</i>, 2009, 41(1):37-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19520272/pubmed\" target=\"_blank\" id=\"19520272\">19520272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kossoff EH, Bergey GK, Freeman JM, et al, &quot;Levetiracetam Psychosis in Children With Epilepsy,&quot; <i>Epilepsia</i>, 2001, 42(12):1611-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/11879376/pubmed\" target=\"_blank\" id=\"11879376\">11879376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kramer G, Hosli I, Glanzmann R et al. Levetiracetam accumulation in human breast milk. <i>Epilepsia</i>. 2002;43 (Suppl 7):105.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&oacute;pez-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. <i>Epilepsy Behav</i>. 2009;15(3):372-375.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19362602 /pubmed\" target=\"_blank\" id=\"19362602 \">19362602 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. <i>J Perinatol</i>. 2013;33(11):841-846.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/24051577 /pubmed\" target=\"_blank\" id=\"24051577 \">24051577 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandelbaum DE, Bunch M, Kugler SL, et al, &quot;Efficacy of Levetiracetam at 12 Months in Children Classified By Seizure Type, Cognitive Status, and Previous Anticonvulsant Drug Use,&quot; <i>J Child Neurol</i>, 2005, 20(7):590-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16159526/pubmed\" target=\"_blank\" id=\"16159526\">16159526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. <i>Neurology</i>. 2013;80(4):400-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23303847 /pubmed\" target=\"_blank\" id=\"23303847 \">23303847 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller GS, &quot;Pyridoxine Ameliorates Adverse Behavioral Effects of Levetiracetam in Children,&quot; <i>Epilepsia</i>, 2002, 43(Suppl 7):S62.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&oslash;lgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. <i>JAMA</i>. 2011;305(19):1996-2002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21586715 /pubmed\" target=\"_blank\" id=\"21586715 \">21586715 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng YT, Hastriter EV, Cardenas JF, et al, &quot;Intravenous Levetiracetam in Children With Seizures: A Prospective Safety Study,&quot; <i>J Child Neurol</i>, 2010, 25(5):551-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/20413804/pubmed\" target=\"_blank\" id=\"20413804\">20413804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Opp J, Tuxhorn I, May T, et al, &quot;Levetiracetam in Children With Refractory Epilepsy: A Multicenter Open Label Study in Germany,&quot; <i>Seizure</i>, 2005, 14(7):476-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/16182573/pubmed\" target=\"_blank\" id=\"16182573\">16182573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paret N, Gouraud A, Bernard N, et al. Long-term follow-up of infants exposed to levetiracetam during breastfeeding: Comparison to a control group. <i>Birth Defects Res A Clin Mol Teratol</i>. 2014;100:537-538.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23911354 /pubmed\" target=\"_blank\" id=\"23911354 \">23911354 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pellock JM, Glauser TA, Bebin EM, et al, &quot;Pharmacokinetic Study of Levetiracetam in Children,&quot; <i>Epilepsia</i>, 2001, 42(12):1574-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/11879369/pubmed\" target=\"_blank\" id=\"11879369\">11879369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry MS and Benatar M, &quot;Efficacy and Tolerability of Levetiracetam in Children Younger Than 4 Years: A Retrospective Review,&quot; <i>Epilepsia</i>, 2007, 48(6):1123-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17430408/pubmed\" target=\"_blank\" id=\"17430408\">17430408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rakshasbhuvankar A, Rao S, Kohan R, Simmer K, Nagarajan L. Intravenous levetiracetam for treatment of neonatal seizures. <i>J Clin Neurosci</i>. 2013;20(8):1165-1167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/23664133 /pubmed\" target=\"_blank\" id=\"23664133 \">23664133 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramantani G, Ikonomidou C, Walter B, et al, &quot;Levetiracetam: Safety and Efficacy in Neonatal Seizures,&quot; <i>Eur J Paediatr Neurol</i>, 2011, 15(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/21094062/pubmed\" target=\"_blank\" id=\"21094062\">21094062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiter PD, Huff AD, Knupp KG, et al, &quot;Intravenous Levetiracetam in the Management of Acute Seizures in Children,&quot; <i>Pediatr Neurol</i>, 2010, 43(2):117-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/20610122/pubmed\" target=\"_blank\" id=\"20610122\">20610122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shoemaker MT and Rotenberg JS, &quot;Levetiracetam for the Treatment of Neonatal Seizures,&quot; <i>J Child Neurol</i>, 2007, 22(1):95-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/17608315/pubmed\" target=\"_blank\" id=\"17608315\">17608315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein FS and Ferriero DM, &quot;Off-Label Use of Antiepileptic Drugs for the Treatment of Neonatal Seizures,&quot; <i>Pediatr Neurol</i>, 2008, 39(2):77-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18639748/pubmed\" target=\"_blank\" id=\"18639748\">18639748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spritam tablets (levetiracetam) [prescribing information]. East Windsor, NJ: Aprecia Pharmaceuticals Company; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomson T, Palm R, K&auml;ll&eacute;n K, et al, &quot;Pharmacokinetics of Levetiracetam During Pregnancy, Delivery, in the Neonatal Period, and Lactation,&quot; <i>Epilepsia</i>, 2007, 48(6):1111-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vaisleib II and Neft RA, &quot;Rapid Dosage Titration of Levetiracetam in Children,&quot; <i>Pharmacotherapy</i>, 2008, 28(3):393-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/18294118/pubmed\" target=\"_blank\" id=\"18294118\">18294118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vajda FJ, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs--the Australian experience. <i>J Clin Neurosci</i>. 2012;19(1):57-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/22104350 /pubmed\" target=\"_blank\" id=\"22104350 \">22104350 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheless JW, Clarke D, Hovinga CA, et al, &quot;Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study,&quot; <i>J Child Neurol</i>, 2009, 24(8):946-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information/abstract-text/19264738/pubmed\" target=\"_blank\" id=\"19264738\">19264738</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12910 Version 258.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187641\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187642\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2875435\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443805\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2875546\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187617\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187603\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46216158\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874650\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2875547\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187636\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2875436\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187675\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187673\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187623\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187607\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022046\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299586\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187612\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F187637\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187614\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187626\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2875551\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187606\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187622\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187625\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187628\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12910|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levetiracetam-drug-information\" class=\"drug drug_general\">Levetiracetam: Drug information</a></li><li><a href=\"topic.htm?path=levetiracetam-patient-drug-information\" class=\"drug drug_patient\">Levetiracetam: Patient drug information</a></li></ul></div></div>","javascript":null}